Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will determine whether or not Lenalidomide improves effectiveness of treatment for
chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the
disease (bendamustine and rituximab).